AMRX Q3 2019 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMRXAmneal Pharmaceuticals, Inc.

$4B

Q3 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$378M-20.6% YoY

Gross Profit

$54M14.4% margin

Operating Income

-$112M-29.7% margin

Net Income

-$265M-70.1% margin

EPS (Diluted)

$-2.03

QoQ Revenue Growth

-6.5%

Cash Flow

Operating Cash Flow

$140M

Free Cash Flow

$127M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$3.7B

Total Liabilities

$3.3B

Stockholders' Equity

$396M

Cash & Equivalents

$213M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$378M	$476M	-20.6%
Gross Profit	$54M	$200M	-72.8%
Operating Income	-$112M	$75M	-250.6%
Net Income	-$265M	$7M	-3911.9%

Revenue Segments

Levothyroxine Sodium

$40M30%

Rytary Family

$34M25%

Epinephrine Auto Injector Family Generic Adrenaclick

$23M17%

Diclofenac Sodium Gel

$19M15%

Oxymorphone

$17M13%